Logo image of CRIS

CURIS INC (CRIS) Stock Price, Quote, News and Overview

NASDAQ:CRIS - Nasdaq - US2312693094 - Common Stock - Currency: USD

3.1  0 (0%)

CRIS Quote, Performance and Key Statistics

CURIS INC

NASDAQ:CRIS (2/21/2025, 8:10:54 PM)

3.1

0 (0%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High17.49
52 Week Low2.86
Market Cap26.26M
Shares8.47M
Float7.80M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-05 2025-05-05/bmo
IPO08-01 2000-08-01


CRIS short term performance overview.The bars show the price performance of CRIS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40 -50

CRIS long term performance overview.The bars show the price performance of CRIS in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of CRIS is 3.1 USD. In the past month the price decreased by -9.62%. In the past year, price decreased by -67.4%.

CURIS INC / CRIS Daily stock chart

CRIS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About CRIS

Company Profile

CRIS logo image Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 48 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.

Company Info

CURIS INC

128 Spring Street, Building C, Suite 500

Lexington MASSACHUSETTS 02421 US

CEO: James Dentzer

Employees: 49

Company Website: https://www.curis.com/

Investor Relations: http://investors.curis.com/

Phone: 16175036500

CURIS INC / CRIS FAQ

What is the stock price of CURIS INC today?

The current stock price of CRIS is 3.1 USD.


What is the ticker symbol for CURIS INC stock?

The exchange symbol of CURIS INC is CRIS and it is listed on the Nasdaq exchange.


On which exchange is CRIS stock listed?

CRIS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CURIS INC stock?

12 analysts have analysed CRIS and the average price target is 21.42 USD. This implies a price increase of 590.97% is expected in the next year compared to the current price of 3.1. Check the CURIS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CURIS INC worth?

CURIS INC (CRIS) has a market capitalization of 26.26M USD. This makes CRIS a Nano Cap stock.


How many employees does CURIS INC have?

CURIS INC (CRIS) currently has 49 employees.


What are the support and resistance levels for CURIS INC (CRIS) stock?

CURIS INC (CRIS) has a support level at 3.07 and a resistance level at 3.37. Check the full technical report for a detailed analysis of CRIS support and resistance levels.


Is CURIS INC (CRIS) expected to grow?

The Revenue of CURIS INC (CRIS) is expected to decline by -6.38% in the next year. Check the estimates tab for more information on the CRIS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CURIS INC (CRIS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CURIS INC (CRIS) stock pay dividends?

CRIS does not pay a dividend.


When does CURIS INC (CRIS) report earnings?

CURIS INC (CRIS) will report earnings on 2025-05-05, before the market open.


What is the Price/Earnings (PE) ratio of CURIS INC (CRIS)?

CURIS INC (CRIS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.81).


What is the Short Interest ratio of CURIS INC (CRIS) stock?

The outstanding short interest for CURIS INC (CRIS) is 2.11% of its float. Check the ownership tab for more information on the CRIS short interest.


CRIS Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

CRIS Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to CRIS. CRIS has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CRIS Financial Highlights

Over the last trailing twelve months CRIS reported a non-GAAP Earnings per Share(EPS) of -7.81. The EPS increased by 16.29% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -107.09%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%20.19%
Sales Q2Q%3.46%
EPS 1Y (TTM)16.29%
Revenue 1Y (TTM)0.38%

CRIS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to CRIS. The Buy consensus is the average rating of analysts ratings from 12 analysts.

For the next year, analysts expect an EPS growth of 21% and a revenue growth -6.38% for CRIS


Ownership
Inst Owners37.99%
Ins Owners7.81%
Short Float %2.11%
Short Ratio1.33
Analysts
Analysts80
Price Target21.42 (590.97%)
EPS Next Y21%
Revenue Next Year-6.38%